Literature DB >> 6509357

Effects of chemotherapeutic agents on the immune response. I.

R A Kempf, M S Mitchell.   

Abstract

Mesh：

Substances：

Year:  1984        PMID： 6509357     DOI： 10.3109/07357908409048519

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  7 in total

Review 1.  A biobehavioral model of cancer stress and disease course.

Authors:  B L Andersen; J K Kiecolt-Glaser; R Glaser
Journal:  Am Psychol       Date:  1994-05

2.  Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; D Bellgrau; J M Eule; J R Parra; Q Kong; K O Lillehei
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

3.  In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.

Authors:  S Peppoloni; B J Mathieson; R B Herberman; R W Overton; E Gorelik
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation.

Authors:  Apostolis Stathopoulos; Chrystel Pretto; Laurent Devillers; Denis Pierre; Florence M Hofman; Carol Kruse; Martin Jadus; Thomas C Chen; Virgil E J C Schijns
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

5.  Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

Authors:  H Onodera; S S Somers; P J Guillou
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

6.  Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance.

Authors:  C K Luk; I F Tannock
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

7.  A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.

Authors:  T J Hamblin; S Sadullah; P Williamson; J Stevenson; R Oskam; P Palmer; C R Franks
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.